Journal of Clinical Oncology
Articles in this Issue
Validation of protein biomarkers for early detection of cervical cancer and squamous intraepithelial lesions.
e17506 Background: Human papillomavirus infections often resolve on their own; however, ongoing high risk HPV infections can progress to cervical cancer,...
Clinicopathologic determinants of survival of hepatoid adenocarcinoma of the stomach: Analysis of a pooled database.
e16018 Background: Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive subtype of gastric cancer characterized by histological and funct...
Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
e23271 Background: BTKis are the standard of care for CLL/SLL in the first-line (1L) and relapsed/refractory (R/R) settings. The next-generation BTKi zanu...
Impact of palliative care on the management and outcomes of elderly pancreatic cancer patients following admissions for acute pulmonary embolism.
e16397 Background: Palliative care (PalC) has improved the quality of life of cancer patients by focusing on holistic support, pain management, and emotio...
Dysphagia in cancers of the lip, oral cavity, and pharynx patients: Impact on cachexia, hospitalization, and racial disparities on outcomes.
e18045 Background: Cancers of the lip, oral cavity, and pharynx (CLOP) are frequently associated with complications arising from tumor location and treatm...
Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data.
11097 Background: Treatment advances in DLBCL have led to remarkable improvements in patient outcomes. Social determinants of health (SDOH) can contribute...
Shared decision-making in follow-up care for lung cancer screening.
12114 Background: Shared decision-making (SDM) is a critical component of lung cancer screening (LCS) decisions to ensure patients understand the benefits...
Characterization of the ctDNA mutational landscape in HER2-positive metastatic breast cancer patients who developed cancer therapy-related cardiac dysfunction.
e24026 Background: Cancer therapy-related cardiac dysfunction (CTRCD) remains a major challenge in managing HER2+ breast cancer due to therapy-induced car...
Long-term lung cancer risk in breast cancer survivors: A 40-year comprehensive analysis.
e12501 Background: Breast cancer survivors face an increased risk of secondary malignancies, with lung cancer being one of the most concerning long-term a...
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06).
1013 Background: DB-06 (NCT04494425), a Phase 3, randomized, open-label study, demonstrated a clinically meaningful progression-free survival (PFS; 13.2 v...
Remote clinical pharmacist impact on reducing total cost of care in Enhancing Oncology Model–enrolled oncology practices.
1501 Background: The national cost of cancer care is estimated to exceed $245 billion by 2030, primarily due to the high cost of cancer drugs....
Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.
2532 Background: Our previous study demonstrated that double-negative T cells (DNTs) hold potential for treating relapsed or refractory acute myeloid leuk...
Body composition modulations during cyclic fasting-mimicking diet in patients with advanced solid cancers.
3156 Background: Fasting-mimicking diets (FMD) can induce favorable immune-metabolic changes in humans and preclinical data suggest potential antitumor ac...
Enhancing competence and confidence in thoracic oncology: A pilot study on the impact of self-assessment and reflection tools for hematology-oncology fellows.
e21019 Background: The knowledge base in oncology is continuously evolving; this poses challenges in evaluating competency of medical trainees.To help adv...
OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal cancer.
TPS3636 Background: Approximately 50% of patients diagnosed with metastatic colorectal cancer (mCRC) are wild-type for KRAS ,...
Association of germline homologous recombination deficiency mutations with HER2 status conversion from negative to positive following neoadjuvant chemotherapy in breast cancer.
1034 Background: Neoadjuvant therapy (NT) is well established in breast cancer management, with subsequent adjuvant therapy guided by biomarker status and...
Visual capturing and profiling of circulating tumor cells from breast cancer patient’s blood via combining fluorescent IMNPs in a magnet-integrated 3D-printed microfluidic chip.
e13038 Background: Circulating tumor cells (CTCs) are considered to be biomarkers of great significance for early metastasis diagnosis, prognosis, and tre...
Efficacy GLP-1 agonists, SGLT-2 inhibitors and other glucose-lowering medications on cardiorenal outcomes in patients with diabetes and cancer on immune checkpoint therapy.
11174 Background: Treatment with Immune checkpoint inhibitors (ICI) therapy has improved survival in multiple malignancies. However, patients with type 2...
Neutrophil-to-lymphocyte ratio (NLR) as an independent prognostic marker in MUTYH- associated colorectal cancers (MUTYH-CRCs).
e15719 Background: MUTYH-associated polyposis (MAP) is a hereditary colorectal cancer (CRC) syndrome caused by biallelic mutations in the MUTYH gene. Unli...
Sequential curative surgery and outcome in a multicenter randomized phase III trial comparing conversion chemotherapy followed by chemoradiotherapy vs continuous chemotherapy in patients with unresectable pancreatic cancer (CONKO-007 trial).
e16458 Background: Secondary surgery is increasingly used in patients with unresectable pancreatic cancer. Objections have been raised about the potential...
Exome analysis of over 5000 esophagogastric cancers.
4073 Background: Esophagogastric cancers (EGCs) encompass a heterogenous group of cancers. The genomic drivers that overlap or differentiate among each ca...
NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors.
e16294 Background: High recurrence rate after resection negatively impacts survival outcomes of patients (Pts) with resectable intrahepatic cholangiocarci...
Surgical outcomes of lenvatinib treatment followed by liver resection for large advanced hepatocellular carcinoma.
e16309 Background: According to the new definition of borderline resectable HCC, large hepatocellular carcinoma ( > 10 cm) is classified as resectable,...
Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study.
TPS5634 Background: Debio 0123 is an oral, highly selective WEE1 inhibitor. WEE1 inhibition leads to S phase and G2/M cell cycle checkpoint bypass, allowi...
From trials to clinics: Real-world outcomes of neoadjuvant HER2 directed therapy in early stage breast cancer using AI-enhanced data pipelines.
e12610 Background: Human Epidermal Growth Factor Receptor 2 (HER2)–positive breast cancers were historically associated with more aggressive disease befor...